Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: Effective and convenient

Journal of the Pancreas

Volumn 11, Issue 2, 2010, Pages 176-182

  Saif, Muhammad Wasif ^a   Kaley, Kristin ^a   Lamb, Lynne ^a   Pecerillo, Jennifer ^a   Hotchkiss, Susan ^a   Steven, Lisa ^a   Brennan, Marianne ^a   Penney, Robin ^a   Gillespie, Carolyn ^a   Shaib, Walid ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cetuximab; Drug therapy; Epidermal growth factor; Erlotinib; Pancreatic neoplasms; Panitumumab; Protein kinase inhibitors; Receptor

Indexed keywords

ABGENIX; ANTI ACNE AGENT; ANTIBIOTIC AGENT; CANERTINIB; CETUXIMAB; DOXYCYCLINE; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HYDROCORTISONE; LAPATINIB; MATUZUMAB; METHYLPREDNISOLONE; NIMOTUZUMAB; PANITUMUMAB; PELITINIB; STEROID; SUNSCREEN; TETRACYCLINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANAPHYLAXIS; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONSULTATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DRY SKIN; EARLY DIAGNOSIS; ELECTRONIC DATA INTERCHANGE; FLUSHING; GASTROINTESTINAL TUMOR; HAIR DISEASE; HUMAN; HUMIDIFIER; HYGIENE; INFECTION RISK; INFORMATION PROCESSING; MUCOSA INFLAMMATION; PANCREAS CANCER; PARONYCHIA; PATIENT EDUCATION; PATIENT MONITORING; PROPHYLAXIS; PRURITUS; QUALITY OF LIFE; SEPSIS; SIDE EFFECT; SKIN CARE; SKIN FISSURE; SKIN TOXICITY; SUPERINFECTION; URTICARIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; AUDIOVISUAL AIDS; CARCINOMA; COMMUNICATION; CONTINUITY OF PATIENT CARE; DRUG TOXICITY; EFFICIENCY; ELECTRONIC MAIL; GASTROINTESTINAL NEOPLASMS; HEALTH SERVICES ACCESSIBILITY; HUMANS; PANCREATIC NEOPLASMS; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN DISEASES; TELECOMMUNICATIONS;

EID: 77749285626     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Li J, Peccerillo J, Kaley K, Saif MW. Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP. J Pancreas (Online) 2009; 10:338-40. [PMID 19454833]
2. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657-70. [PMID 17010747]
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677]
4. Boeck S, Hausmann A, Reibke R, Schulz C, Heinemann V. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 2007; 18:1109-11. [PMID 17704662]
5. Saif MW. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006. JOP. J Pancreas (Online) 2006; 7:337-48. [PMID 16832131]
6. Gutzmer R, Werfel T, Kapp A, Elsner J. Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt 2006; 57:509-13. [PMID 16205868]
7. Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C, Viganò MG, et al. Clinical significance of skin toxicity due to EGFRtargeted therapies. J Oncol 2009; 849051:1-8. [PMID 19584908]
8. Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10:345-56. [PMID 15851793]
9. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85. [PMID 14701768]
10. Tan AR, Steinberg SM, Parr AL, Nguyen D, Yang SX. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann Oncol 2008; 19:185-90. [PMID 17878175]
11. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). CTEP: Cancer Therapy Evaluation Program. Publish date August 9, 2006 Accessed January 14, 2008.
12. Saif MW, Merikas I, Tsimboukis S, Syrigos K. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP. J Pancreas (Online) 2008; 9:267-74. [PMID 18469438]
13. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12:610-21. [PMID 17522250]
14. Genentech. Inc. Tarceva® . Highlights of Prescribing Information. Accessed February 19, 2007.
15. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6:175-82. [PMID 17367263]
16. Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598-601. [PMID 12207609]
17. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 2006; 22(Suppl 1):28-34. [PMID 16616284]
18. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54:258-65. [PMID 16443056]
19. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010 Feb 8. [PMID 20142600]
20. Saif MW, Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:118-24. [PMID 16945167]
21. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009; 9:1199-206. [PMID 19624281]
22. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8. [PMID 14993230]
23. Saltz LB, Rubin M, Hochster H, et al. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a. Abstract 7.
24. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45. [PMID 15269313]
25. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-21. [PMID 17606725]
26. Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, et al. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 2009; 66:257-61. [PMID 19231023]
27. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004; 22:2610-6. [PMID 15226328]
28. Kies M, Arquette MA, Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Cetuximab (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002; Abstract 925.
29. Kane B, Sands DZ. White paper: guidelines for the clinical use of electronic mail with patients. J Am Med Inform Assoc 1998; 5:104-11. [PMID 9452989]